News & Updates

Findings from the DOTS trial presented at ESCMID Global 2024 underpin the potential of dalbavancin, a long-acting lipoglycopeptide, for the management of complicated Staphylococcus (S.) aureus bacteraemia (SAB) without requiring long-term vascular access.

About half of individuals with chronic pouchitis respond to ustekinumab, as shown in a prospective study.

Administering corticosteroids during pregnancy leads to improved postnatal growth in infants born extremely or very preterm, as shown in a study.

Adverse drug events commonly occur in the outpatient setting and are often serious, a study has shown. In addition, adverse event (AE) rates are greater in older adults.

In the second-line treatment of patients with metastatic colorectal cancer harbouring KRAS mutation, onvansertib combined with FOLIFRI/bevacizumab demonstrates promising clinical activity while having a manageable safety profile, according to the results of a phase Ib study.

In people with rheumatic and musculoskeletal diseases (RMDs), inactivated COVID-19 vaccines prove safe and effective at lowering the risk of COVID-19–related pneumonia, as shown in a study from China.

The plant-based alkaloid cytisinicline, when coupled with behavioural support, shows promise in the treatment of e-cigarette users who seek to break the habit.